444 related articles for article (PubMed ID: 30580564)
1. Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.
Reyes-Soffer G; Sztalryd C; Horenstein RB; Holleran S; Matveyenko A; Thomas T; Nandakumar R; Ngai C; Karmally W; Ginsberg HN; Ramakrishnan R; Pollin TI
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):63-72. PubMed ID: 30580564
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
3. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
4. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
Murdoch SJ; Breckenridge WC
Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
[TBL] [Abstract][Full Text] [Related]
5. Effect of lipid transfer proteins on lipoprotein lipase induced transformation of VLDL and HDL.
Murdoch SJ; Breckenridge WC
Biochim Biophys Acta; 1996 Oct; 1303(3):222-32. PubMed ID: 8908157
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of apolipoproteins C-II, C-III, and B in hypertriglyceridemic men. Changes after heparin-induced lipolysis.
Huff MW; Breckenridge WC; Strong WL; Wolfe BM
Arteriosclerosis; 1988; 8(5):471-9. PubMed ID: 3190554
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.
Mendivil CO; Zheng C; Furtado J; Lel J; Sacks FM
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):239-45. PubMed ID: 19910636
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.
Ooi EM; Russell BS; Olson E; Sun SZ; Diffenderfer MR; Lichtenstein AH; Keilson L; Barrett PH; Schaefer EJ; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):459-66. PubMed ID: 22095987
[TBL] [Abstract][Full Text] [Related]
9. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
[TBL] [Abstract][Full Text] [Related]
10. [Composition and distribution of lipid and apolipoprotein in plasma lipoproteins of endogenous hypertriglyceridemia].
Zhang L; Liu B
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):117-21. PubMed ID: 1452137
[TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice.
Takahashi T; Hirano T; Okada K; Adachi M
Metabolism; 2003 Oct; 52(10):1354-9. PubMed ID: 14564689
[TBL] [Abstract][Full Text] [Related]
13. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
[TBL] [Abstract][Full Text] [Related]
14. Effect of human high density lipoproteins, anti-apolipoproteins CII and CIII, and hydrolysis of very low density lipoprotein (VLDL) cholesterol ester on VLDL catabolism in vitro.
Liu BW; Hynd BA; Kashyap ML
Biochem Biophys Res Commun; 1984 Jun; 121(3):946-52. PubMed ID: 6588972
[TBL] [Abstract][Full Text] [Related]
15. In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase.
Chung BH; Segrest JP; Franklin F
Atherosclerosis; 1998 Dec; 141(2):209-25. PubMed ID: 9862170
[TBL] [Abstract][Full Text] [Related]
16. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
Lee SJ; Sacks FM
Am J Cardiol; 2003 Jul; 92(2):121-4. PubMed ID: 12860210
[TBL] [Abstract][Full Text] [Related]
17. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K; Fisher EA; Chen X; Chajek-Shaul T; Hayek T; Zechner R; Walsh A; Ramakrishnan R; Ginsberg HN; Breslow JL
J Clin Invest; 1992 Nov; 90(5):1889-900. PubMed ID: 1430212
[TBL] [Abstract][Full Text] [Related]
19. Effects of omega-3 fatty acids on intravascular lipolysis of very-low-density lipoproteins in humans.
Kasim-Karakas SE; Herrmann R; Almario R
Metabolism; 1995 Sep; 44(9):1223-30. PubMed ID: 7666799
[TBL] [Abstract][Full Text] [Related]
20. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
Taskinen MR; Björnson E; Matikainen N; Söderlund S; Rämö J; Ainola MM; Hakkarainen A; Sihlbom C; Thorsell A; Andersson L; Bergh PO; Henricsson M; Romeo S; Adiels M; Ripatti S; Laakso M; Packard CJ; Borén J
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
